The lack of significant differences in survival outcomes between patients with high and low CDX2 expression who received adjuvant chemotherapy for rectal cancer suggests that CDX2 expression likely does not predict response to chemotherapy in this population. The gene discussed is CDX2; the disease is rectal cancer.